Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00291
|
|||||
Drug Name |
Cisplatin
|
|||||
Synonyms |
(SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Abiplatin; Biocisplatinum; Briplatin; Cis-DDP; Cis-Diamminedichloroplatinum; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Cismaplat; Cisplatin (Chemotherapy); Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Peyrone's chloride; Peyrone's salt; Plastin; Platamine; Platidiam; Platinoxan; Randa; Trans-diamminedichloridoplatinum(II)
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Ovarian cancer [ICD11: 2C73] | Approved | [1] | |||
Sarcomas [ICD11: 2C35] | Approved | [1] | ||||
Testicular cancer [ICD11: 2C80] | Approved | [1] | ||||
Therapeutic Class |
Anticancer Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
Cl2H6N2Pt+2
|
|||||
Canonical SMILES |
N.N.Cl[Pt+2]Cl
|
|||||
InChI |
InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+4/p-2
|
|||||
InChIKey |
BSJGASKRWFKGMV-UHFFFAOYSA-L
|
|||||
CAS Number |
CAS 15663-27-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 300.05 | Topological Polar Surface Area | 2 | ||
Heavy Atom Count | 5 | Rotatable Bond Count | 0 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 2 | |||
PubChem CID | ||||||
PubChem SID | ||||||
ChEBI ID |
ChEBI:27899
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | ATP7B | Transporter Info | Copper-transporting ATPase 2 | Substrate | [2] | |
BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
COPT2 | Transporter Info | Probable low affinity copper uptake protein 2 | Substrate | [4] | ||
CTR1 | Transporter Info | High affinity copper uptake protein 1 | Substrate | [5] | ||
MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [6] | ||
MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [7] | ||
MRP6 | Transporter Info | Multidrug resistance-associated protein 6 | Substrate | [8] | ||
OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [9] | ||
OCT-2 | Transporter Info | Organic cation transporter 2 | Substrate | [10] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [11] | ||
References | ||||||
1 | Cisplatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Effect of cisplatin on the transport activity of PII-type ATPases. Metallomics. 2017 Jul 19;9(7):960-968. | |||||
3 | Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93. | |||||
4 | Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol. 2011 Jan;79(1):157-66. | |||||
5 | Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61. | |||||
6 | Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14. | |||||
7 | Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55. | |||||
8 | Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. | |||||
9 | Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86. | |||||
10 | Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84. | |||||
11 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.